PDCD1 and cancer: Among the clinicians who returned valid questionnaires, nearly 60% had prescribed PD-1/PD-L1 inhibitors, which indicates that Chinese clinicians are actively exploring the best role for immunotherapy in patients suffering from cancer in China.